Frontiers in Immunology (Jul 2024)

LINC00518: a key player in tumor progression and clinical outcomes

  • Qiang Yi,
  • Gangfeng Zhu,
  • Weijian Zhu,
  • Jiaqi Wang,
  • Xinting Ouyang,
  • Kuan Yang,
  • Jinghua Zhong

DOI
https://doi.org/10.3389/fimmu.2024.1419576
Journal volume & issue
Vol. 15

Abstract

Read online

Long non-coding RNAs (lncRNAs), defined as RNA molecules exceeding 200 nucleotides in length, have been implicated in the regulation of various biological processes and the progression of tumors. Among them, LINC00518, a recently identified lncRNA encoded by a gene located on chromosome 6p24.3, consists of three exons and is predicted to positively regulate the expression of specific genes. LINC00518 has emerged as a key oncogenic lncRNA in multiple cancer types. It exerts its tumor-promoting effects by modulating the expression of several target genes, primarily through acting as a sponge for microRNAs (miRNAs). Additionally, LINC00518 influences critical signaling pathways, including the Wnt/β-catenin, JAK/STAT, and integrin β3/FAK pathways. Elevated levels of LINC00518 in tumor tissues are associated with increased tumor size, advanced clinical stage, metastasis, and poor survival prognosis. This review provides a comprehensive summary of the genetic characteristics, expression patterns, biological functions, and underlying mechanisms of LINC00518 in human diseases.

Keywords